Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
MPTP
Parkinson's disease
dopamine
macaque monkey
thalamus
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
03
09
2019
revised:
08
10
2019
accepted:
21
10
2019
pubmed:
5
12
2019
medline:
28
4
2021
entrez:
5
12
2019
Statut:
ppublish
Résumé
Dopamine loss beyond the mesostriatal system might be relevant in pathogenic mechanisms and some clinical manifestations in PD. The primate thalamus is densely and heterogeneously innervated with dopaminergic axons, most of which express the dopamine transporter, as does the nigrostriatal system. We hypothesized that dopamine depletion may be present in the thalamus of the parkinsonian brain and set out to ascertain possible regional differences. The toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered to adult macaque monkeys using a slow intoxication protocol. The treated macaques were classified into 2 groups according to their motor status: nonsymptomatic and parkinsonian. Dopamine innervation was studied with immunohistochemistry for the dopamine transporter. Topographic maps of the dopamine transporter-immunoreactive axon distribution were generated and the total length and length density of these axons stereologically estimated using a 3-dimensional fractionator. Parkinsonian macaques exhibited lower dopamine transporter-immunoreactive axon length density than controls in mediodorsal and centromedian-parafascicular nuclei. Dopamine denervation in the mediodorsal nucleus was already noticeable in nonsymptomatic macaques and was even greater in parkinsonian macaques. Reticular nucleus dopamine transporter-immunoreactive axon length density presented an inverse pattern, increasing progressively to the maximum density seen in parkinsonian macaques. No changes were observed in ventral thalamic nuclei. Dopamine transporter-immunoreactive axon maps supported the quantitative findings. Changes in the dopamine innervation of various thalamic nuclei are heterogeneous and start in the premotor parkinsonian stage. These changes may be involved in some poorly understood nonmotor manifestations of PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Dopamine loss beyond the mesostriatal system might be relevant in pathogenic mechanisms and some clinical manifestations in PD. The primate thalamus is densely and heterogeneously innervated with dopaminergic axons, most of which express the dopamine transporter, as does the nigrostriatal system. We hypothesized that dopamine depletion may be present in the thalamus of the parkinsonian brain and set out to ascertain possible regional differences.
METHODS
The toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered to adult macaque monkeys using a slow intoxication protocol. The treated macaques were classified into 2 groups according to their motor status: nonsymptomatic and parkinsonian. Dopamine innervation was studied with immunohistochemistry for the dopamine transporter. Topographic maps of the dopamine transporter-immunoreactive axon distribution were generated and the total length and length density of these axons stereologically estimated using a 3-dimensional fractionator.
RESULTS
Parkinsonian macaques exhibited lower dopamine transporter-immunoreactive axon length density than controls in mediodorsal and centromedian-parafascicular nuclei. Dopamine denervation in the mediodorsal nucleus was already noticeable in nonsymptomatic macaques and was even greater in parkinsonian macaques. Reticular nucleus dopamine transporter-immunoreactive axon length density presented an inverse pattern, increasing progressively to the maximum density seen in parkinsonian macaques. No changes were observed in ventral thalamic nuclei. Dopamine transporter-immunoreactive axon maps supported the quantitative findings.
CONCLUSIONS
Changes in the dopamine innervation of various thalamic nuclei are heterogeneous and start in the premotor parkinsonian stage. These changes may be involved in some poorly understood nonmotor manifestations of PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 31800134
doi: 10.1002/mds.27921
pmc: PMC7154739
doi:
Substances chimiques
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
9P21XSP91P
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-430Informations de copyright
© 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Références
J Neural Transm (Vienna). 2003 Jun;110(6):591-601
pubmed: 12768355
Front Neuroanat. 2018 Jun 12;12:49
pubmed: 29946242
Ann Neurol. 2001 Sep;50(3):321-9
pubmed: 11558788
J Neurosci. 2005 Jun 29;25(26):6076-83
pubmed: 15987937
Parkinsonism Relat Disord. 2018 Jun;51:43-48
pubmed: 29526657
Neuroimage. 2003 Oct;20(2):1064-75
pubmed: 14568476
Neurosci Biobehav Rev. 2015 Jul;54:76-88
pubmed: 25757689
J Comp Neurol. 1991 Nov 1;313(1):65-94
pubmed: 1761756
Eur J Neurosci. 2004 Sep;20(5):1371-8
pubmed: 15341609
J Neurosci. 2000 Jul 1;20(13):5102-14
pubmed: 10864967
J Comp Neurol. 1995 Nov 20;362(3):400-10
pubmed: 8576447
J Chem Neuroanat. 1995 May;8(4):245-57
pubmed: 7545406
Front Neuroanat. 2018 May 15;12:38
pubmed: 29867377
Brain. 2013 Aug;136(Pt 8):2419-31
pubmed: 23884810
Nat Rev Neurosci. 2018 Feb;19(2):107-118
pubmed: 29321683
J Microsc. 1998 Sep;191(3):238-248
pubmed: 9767488
Trends Cogn Sci. 2018 Nov;22(11):1011-1025
pubmed: 30236489
J Neural Transm Suppl. 1995;45:27-34
pubmed: 8748606
J Neurochem. 2013 Jun;125(5):657-62
pubmed: 23331162
Neuroscience. 2006 Dec 1;143(2):477-86
pubmed: 17008017
J Microsc. 2002 Apr;206(Pt 1):54-64
pubmed: 12000563
Cereb Cortex. 1997 Sep;7(6):583-604
pubmed: 9276182
J Comp Neurol. 2010 Apr 15;518(8):1283-300
pubmed: 20151360
Eur J Neurosci. 2000 Aug;12(8):2892-900
pubmed: 10971632
Basal Ganglia. 2011 Nov 1;1(4):179-189
pubmed: 22773963
Neurochem Int. 1990;17(2):263-70
pubmed: 20504626
Neuroimage. 2007 Feb 1;34(3):965-84
pubmed: 17140815
Eur J Neurosci. 2009 Feb;29(3):588-98
pubmed: 19175404
Brain Struct Funct. 2014 Jan;219(1):381-94
pubmed: 23508713
Ann Neurol. 2000 Mar;47(3):345-52
pubmed: 10716254
Neurodegeneration. 1995 Sep;4(3):245-55
pubmed: 8581557
Brain Res Bull. 2009 Feb 16;78(2-3):113-8
pubmed: 18812214
Mov Disord. 2012 Apr 15;27(5):617-26
pubmed: 22508280
Neuroscience. 1991;44(3):591-605
pubmed: 1754053
Front Neuroanat. 2010 Oct 27;4:139
pubmed: 21103009
Cereb Cortex. 2009 Feb;19(2):424-34
pubmed: 18550594
J Comp Neurol. 1985 Dec 22;242(4):535-60
pubmed: 2418080
Nat Commun. 2016 Jan 25;7:10423
pubmed: 26804245
J Comp Neurol. 2001 Jan 8;429(2):321-36
pubmed: 11116223
J Neurosci. 2009 Jan 14;29(2):444-53
pubmed: 19144844
J Neurosci. 2006 Jul 12;26(28):7348-61
pubmed: 16837581
J Neurosci. 2001 Sep 1;21(17):6853-61
pubmed: 11517273
J Comp Neurol. 1990 Apr 15;294(3):356-61
pubmed: 2341615
Neurobiol Dis. 2010 Jun;38(3):456-63
pubmed: 20304066
Mov Disord. 1991;6(2):111-8
pubmed: 2057003
Neurobiol Dis. 2012 Oct;48(1):79-91
pubmed: 22677034
Mol Neurobiol. 2003 Dec;28(3):209-18
pubmed: 14709785
Neuroscience. 1988 Feb;24(2):379-431
pubmed: 2452377
Brain. 1994 Jun;117 ( Pt 3):531-43
pubmed: 8032863
J Microsc. 1987 Sep;147(Pt 3):229-63
pubmed: 3430576
Annu Rev Neurosci. 1986;9:357-81
pubmed: 3085570